phrykt

Belite Bio, Inc (BLTE): who owns it and who trades it

As of Nov 16, 2026, BLTE insiders reported 178 open-market sales worth $40.9M and no purchases in the last 12 months, with 1% of the sale value made under pre-set 10b5-1 plans. The largest seller was Yu-Hsin Lin (CEO), with $20.8M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Belite Bio

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns BLTE

81 funds and institutions reported BLTE shares worth $1.4B at the end of Q2 2026, about 24% of the company. The largest holder is Darwin Global Management, Ltd. with 7.8%.

Funds and institutions (13F) 24%Everyone else 76%

10 largest owners, by share of the company

Darwin Global Management, Ltd.7.8%
Paradigm Biocapital Advisors LP3.1%
Rtw Investments, LP1.8%
Millennium Management LLC1.3%
Maverick Capital Ltd1.0%
Eventide Asset Management, LLC1.0%
Deerfield Management Company, L.P.0.9%
Holocene Advisors, LP0.6%
Logos Global Management LP0.6%
Morgan Stanley0.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Darwin Global Management, Ltd.3.08M7.82%$457M+1%
Paradigm Biocapital Advisors LP1.23M3.13%$190M+11%
Rtw Investments, LP715,3321.82%$110MNo change
Millennium Management LLC494,5641.26%$76.2M-13%
Maverick Capital Ltd396,3111.01%$61MNew
Eventide Asset Management, LLC390,8290.99%$60.2M+9%
Deerfield Management Company, L.P.357,1990.91%$55M+17%
Holocene Advisors, LP251,0350.64%$38.7M-49%
Logos Global Management LP250,0000.64%$38.5MNew
Morgan Stanley235,0710.60%$36.2M+17%
UBS Group AG224,9890.57%$34.6M-71%
Citadel Advisors LLC186,1680.47%$28.7M+9171%
Goldman Sachs Group Inc166,1880.42%$25.6M+58%
Affinity Asset Advisors, LLC165,0000.42%$25.4M+154%
Mpm Bioimpact LLC137,2080.35%$21.1M+56%
Bank of America Corp124,7830.32%$19.2M+3203%
Patient Square Capital LP110,0000.28%$16.9M-6%
Duquesne Family Office LLC106,1000.27%$16.3MNo change
T. Rowe Price Associates105,8590.27%$16.3M-62%
Jane Street Group, LLC65,8010.17%$10.1M+438%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, BLTE insiders reported $0 of open-market purchases and $40.9M of sales. 1% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$40.9M
178 trades, 5 people
Sales under a 10b5-1 plan
1%
Share of sale value
Latest trade
Nov 12, 2026
Filed Nov 16, 2026

Purchases and sales by month

$31.9M$31.9MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 12, 2026Hendrik Peter SchollChief Medical OfficerSale plan500$162.04$81KForm 4
Nov 12, 2026Hendrik Peter SchollChief Medical OfficerSale plan500$164.68$82.3KForm 4
Nov 12, 2026Hendrik Peter SchollChief Medical OfficerSale plan500$166.82$83.4KForm 4
Nov 12, 2026Hendrik Peter SchollChief Medical OfficerSale plan500$170.41$85.2KForm 4
Oct 1, 2026Hendrik Peter SchollChief Medical OfficerSale plan200$163.62$32.7KForm 4
Oct 1, 2026Hendrik Peter SchollChief Medical OfficerSale plan24$164.64$4KForm 4
Oct 1, 2026Hendrik Peter SchollChief Medical OfficerSale plan120$165.49$19.9KForm 4
Oct 1, 2026Hendrik Peter SchollChief Medical OfficerSale plan50$166.44$8.3KForm 4
Oct 1, 2026Hendrik Peter SchollChief Medical OfficerSale plan78$167.59$13.1KForm 4
Oct 1, 2026Hendrik Peter SchollChief Medical OfficerSale plan12$168.21$2KForm 4
Oct 1, 2026Hendrik Peter SchollChief Medical OfficerSale plan14$169.36$2.4KForm 4
Oct 1, 2026Hendrik Peter SchollChief Medical OfficerSale plan2$170.02$340Form 4
Sep 8, 2026Yu-Hsin LinCEOSale6,058$196.54$1.2MForm 4
Sep 8, 2026Yu-Hsin LinCEOSale8,752$197.36$1.7MForm 4
Sep 8, 2026Yu-Hsin LinCEOSale2,700$198.09$535KForm 4
Sep 8, 2026Yu-Hsin LinCEOSale2,400$194.33$466KForm 4
Sep 8, 2026Yu-Hsin LinCEOSale6,090$195.62$1.2MForm 4
Sep 8, 2026Hao-Yuan ChuangCFOSale2,562$198.05$507KForm 4
Sep 8, 2026Hao-Yuan ChuangCFOSale2,200$194.28$427KForm 4
Sep 8, 2026Hao-Yuan ChuangCFOSale4,120$195.60$806KForm 4
Sep 8, 2026Hao-Yuan ChuangCFOSale4,475$196.47$879KForm 4
Sep 8, 2026Hao-Yuan ChuangCFOSale4,605$197.23$908KForm 4
Sep 4, 2026Yu-Hsin LinCEOSale8,111$193.13$1.6MForm 4
Sep 4, 2026Yu-Hsin LinCEOSale2,635$180.29$475KForm 4
Sep 4, 2026Yu-Hsin LinCEOSale2,587$181.24$469KForm 4
Sep 4, 2026Yu-Hsin LinCEOSale3,413$182.50$623KForm 4
Sep 4, 2026Yu-Hsin LinCEOSale4,955$183.30$908KForm 4
Sep 4, 2026Yu-Hsin LinCEOSale6,252$184.52$1.2MForm 4
Sep 4, 2026Yu-Hsin LinCEOSale4,593$185.34$851KForm 4
Sep 4, 2026Yu-Hsin LinCEOSale7,800$186.32$1.5MForm 4
Sep 4, 2026Yu-Hsin LinCEOSale6,200$187.25$1.2MForm 4
Sep 4, 2026Yu-Hsin LinCEOSale3,045$188.26$573KForm 4
Sep 4, 2026Yu-Hsin LinCEOSale8,955$189.34$1.7MForm 4
Sep 4, 2026Yu-Hsin LinCEOSale600$190.39$114KForm 4
Sep 4, 2026Yu-Hsin LinCEOSale11,080$191.15$2.1MForm 4
Sep 4, 2026Yu-Hsin LinCEOSale4,209$192.54$810KForm 4
Sep 4, 2026Hao-Yuan ChuangCFOSale1,633$180.16$294KForm 4
Sep 4, 2026Hao-Yuan ChuangCFOSale2,000$182.49$365KForm 4
Sep 4, 2026Hao-Yuan ChuangCFOSale3,759$183.27$689KForm 4
Sep 4, 2026Hao-Yuan ChuangCFOSale3,569$184.57$659KForm 4
Sep 4, 2026Hao-Yuan ChuangCFOSale3,872$185.28$717KForm 4
Sep 4, 2026Hao-Yuan ChuangCFOSale4,600$186.35$857KForm 4
Sep 4, 2026Hao-Yuan ChuangCFOSale3,900$187.16$730KForm 4
Sep 4, 2026Hao-Yuan ChuangCFOSale1,900$188.59$358KForm 4
Sep 4, 2026Hao-Yuan ChuangCFOSale6,200$189.22$1.2MForm 4
Sep 4, 2026Hao-Yuan ChuangCFOSale1,800$190.63$343KForm 4
Sep 4, 2026Hao-Yuan ChuangCFOSale6,200$191.09$1.2MForm 4
Sep 4, 2026Hao-Yuan ChuangCFOSale3,398$192.40$654KForm 4
Sep 4, 2026Hao-Yuan ChuangCFOSale4,602$193.12$889KForm 4
Sep 4, 2026Hao-Yuan ChuangCFOSale2,000$181.05$362KForm 4
Aug 12, 2026Hao-Yuan ChuangCFOSale144$180.00$25.9KForm 4
Aug 12, 2026Hao-Yuan ChuangCFOSale223$180.57$40.3KForm 4
Aug 12, 2026Yu-Hsin LinCEOSale142$180.00$25.6KForm 4
Jun 18, 2026Hendrik Peter SchollChief Medical OfficerSale3,748$144.66$542KForm 4
Jun 18, 2026Hendrik Peter SchollChief Medical OfficerSale96$147.11$14.1KForm 4
Jun 18, 2026Hendrik Peter SchollChief Medical OfficerSale1,199$146.24$175KForm 4
Jun 18, 2026Hendrik Peter SchollChief Medical OfficerSale4,861$145.43$707KForm 4
Jun 18, 2026Hendrik Peter SchollChief Medical OfficerSale96$143.90$13.8KForm 4
Jun 16, 2026Hendrik Peter SchollChief Medical OfficerSale784$138.18$108KForm 4
Jun 16, 2026Hendrik Peter SchollChief Medical OfficerSale2,054$137.61$283KForm 4
Jun 16, 2026Hendrik Peter SchollChief Medical OfficerSale1,035$145.02$150KForm 4
Jun 16, 2026Hendrik Peter SchollChief Medical OfficerSale3,140$139.57$438KForm 4
Jun 16, 2026Hendrik Peter SchollChief Medical OfficerSale540$140.58$75.9KForm 4
Jun 16, 2026Hendrik Peter SchollChief Medical OfficerSale100$141.83$14.2KForm 4
Jun 16, 2026Hendrik Peter SchollChief Medical OfficerSale450$142.20$64KForm 4
Jun 16, 2026Hendrik Peter SchollChief Medical OfficerSale1,897$143.55$272KForm 4
May 7, 2026Nathan L. MataChief Scientific OfficerSale3$154.61$464Form 4
May 7, 2026Nathan L. MataChief Scientific OfficerSale428$153.56$65.7KForm 4
May 7, 2026Nathan L. MataChief Scientific OfficerSale9$155.25$1.4KForm 4
May 7, 2026Nathan L. MataChief Scientific OfficerSale226$152.45$34.5KForm 4
May 6, 2026Nathan L. MataChief Scientific OfficerSale240$154.41$37.1KForm 4
May 6, 2026Nathan L. MataChief Scientific OfficerSale100$155.97$15.6KForm 4
May 6, 2026Nathan L. MataChief Scientific OfficerSale8$151.57$1.2KForm 4
May 6, 2026Nathan L. MataChief Scientific OfficerSale424$152.67$64.7KForm 4
May 6, 2026Nathan L. MataChief Scientific OfficerSale128$153.42$19.6KForm 4
May 6, 2026Nathan L. MataChief Scientific OfficerSale100$156.00$15.6KForm 4
May 5, 2026Nathan L. MataChief Scientific OfficerSale68$158.11$10.8KForm 4
May 5, 2026Nathan L. MataChief Scientific OfficerSale155$157.29$24.4KForm 4
May 5, 2026Nathan L. MataChief Scientific OfficerSale173$155.48$26.9KForm 4
May 5, 2026Nathan L. MataChief Scientific OfficerSale363$154.44$56.1KForm 4
May 5, 2026Nathan L. MataChief Scientific OfficerSale120$153.92$18.5KForm 4
May 5, 2026Nathan L. MataChief Scientific OfficerSale121$156.53$18.9KForm 4
May 4, 2026Nathan L. MataChief Scientific OfficerSale172$157.49$27.1KForm 4
May 4, 2026Nathan L. MataChief Scientific OfficerSale235$156.57$36.8KForm 4
May 4, 2026Nathan L. MataChief Scientific OfficerSale325$155.21$50.4KForm 4
May 4, 2026Nathan L. MataChief Scientific OfficerSale236$154.24$36.4KForm 4
May 4, 2026Nathan L. MataChief Scientific OfficerSale32$153.50$4.9KForm 4
May 1, 2026Nathan L. MataChief Scientific OfficerSale288$154.38$44.5KForm 4
May 1, 2026Nathan L. MataChief Scientific OfficerSale346$155.48$53.8KForm 4
May 1, 2026Nathan L. MataChief Scientific OfficerSale52$153.89$8KForm 4
May 1, 2026Nathan L. MataChief Scientific OfficerSale82$156.24$12.8KForm 4
May 1, 2026Nathan L. MataChief Scientific OfficerSale106$157.45$16.7KForm 4
May 1, 2026Nathan L. MataChief Scientific OfficerSale65$158.35$10.3KForm 4
May 1, 2026Nathan L. MataChief Scientific OfficerSale38$159.08$6KForm 4
May 1, 2026Nathan L. MataChief Scientific OfficerSale23$160.00$3.7KForm 4
Apr 30, 2026Nathan L. MataChief Scientific OfficerSale101$158.15$16KForm 4
Apr 30, 2026Nathan L. MataChief Scientific OfficerSale42$155.68$6.5KForm 4
Apr 30, 2026Nathan L. MataChief Scientific OfficerSale340$157.37$53.5KForm 4
Apr 30, 2026Nathan L. MataChief Scientific OfficerSale517$156.59$81KForm 4
Apr 29, 2026Nathan L. MataChief Scientific OfficerSale102$157.39$16.1KForm 4

Latest 100 of 178 trades in the last 12 months.

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Yu-Hsin LinChief Executive Officer, Director–$20.8MSep 8, 2026
Hao-Yuan ChuangChief Financial Officer, Director–$14MSep 8, 2026
Hendrik Peter SchollChief Medical Officer–$3.3MNov 12, 2026
Nathan L. MataChief Scientific Officer–$2.7MMay 7, 2026
Wan-Shan ChenDirector–$198KApr 9, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

BLTE short interest

1.38M BLTE shares are sold short. Over the last 12 reports the number of shares short went up 16%.

As of Oct 30, 2026, 1.38M BLTE shares were sold short, up 8.9% from the report before. At the average daily volume of 138,665 shares, buying them all back would take about 10.0 trading days (days to cover).

Shares short, % of all shares

3.34%May 15Jul 153.42%

Days to cover

10.0May 15Oct 3010.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.38M–+9%138,66510.0
Oct 15, 20261.27M–+20%178,3627.1
Sep 30, 20261.06M–+1%145,2067.3
Sep 15, 20261.05M–+0%274,2173.8
Aug 31, 20261.05M–-6%141,5287.4
Aug 14, 20261.12M–-2%191,2735.8
Jul 31, 20261.13M–-14%168,8036.7
Jul 15, 20261.32M3.34%+0%186,3307.1
Jun 30, 20261.31M3.34%-1%247,0775.3
Jun 15, 20261.32M3.37%+10%238,1005.6
May 29, 20261.20M3.05%+1%242,5995.0
May 15, 20261.19M3.03%-3%122,8319.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Belite Bio financials

Famous investors that hold BLTE

5 of the 50 well-known investors we track reported holding BLTE in their latest 13F filing. The largest position is Lee Ainslie's, worth $104M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Lee Ainslie · Maverick CapitalQ3 2026609,906$104M0.8%+54%
Israel Englander · Millennium ManagementQ3 2026375,066$63.7M0.0%-24%
Stanley Druckenmiller · Duquesne Family OfficeQ3 2026106,100$18M0.4%No change
Jim Simons · Renaissance TechnologiesQ3 202632,800$5.6M0.0%-41%
Steve Cohen · Point72 Asset ManagementQ3 202619,143$3.3M0.0%-63%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Belite Bio, Inc (BLTE) stock

Who owns the most BLTE stock?

The largest reported owner of Belite Bio, Inc (BLTE) is Darwin Global Management, Ltd., with 7.8% of the company. In total, 81 funds and institutions reported holding BLTE at the end of Q2 2026, together about 24% of the shares. See the largest owners.

Are BLTE insiders buying or selling?

In the last 12 months, BLTE insiders reported no open-market purchases and 178 sales worth $40.9M. The latest trade was on Nov 12, 2026. See every trade.

What is the short interest in BLTE?

As of Oct 30, 2026, 1.38M BLTE shares were sold short, up 8.9% from the report before. At the average daily volume of 138,665 shares, buying them all back would take about 10.0 trading days (days to cover). See the history.

Which famous investors hold BLTE?

5 of the 50 well-known investors we track reported BLTE in their latest 13F filing, including Lee Ainslie, Israel Englander, Stanley Druckenmiller. The largest position is worth $104M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.